Healthcare ❯ Clinical Trials

Phase 2 Trials

Drug Efficacy Depression Treatment Drug Development Randomized Controlled Trials Ozureprubart Trials Male Contraceptive Trials Phase 3 Trials IL-1 Antibodies

SK Biopharmaceuticals Licenses Biohaven’s Opakalim in Deal Worth Up to $795 Million

The agreement transfers development funding and commercial control for a Kv7 epilepsy program to SK pending US antitrust approval.

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug

AbbVie Agrees to Buy Gilgamesh’s Bretisilocin for Up to $1.2 Billion